Drug Trial Radar · NCT00918411
A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome
Last checked: Nov 20, 2026Latest source record: Oct 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
Jun 2009
Primary completion
Dec 2009
Study completion Dec 2009
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 11, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Who can join
- Male only, from 20 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to explore and examine endpoints that allow evaluation of the "clinically significant improvements, focusing on the patient's chief complaint and the severity of major IBS symptoms" by this drug in patients with diarrhea-predominant irritable bowel syndrome (IBS).
Conditions
- Irritable Bowel Syndrome
Interventions
RamosetronDrug
oral
PlaceboDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- IBS severity index (Japanese version)Time frame: 12 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Hokkaido, Japan
Site not named
Kansai, Japan
Site not named
Kantou, Japan
Site not named
Kyusyu, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.